New spin-out to target Chinese market
Professor Cui, who will work with a team of consultants to screen technologies for the Chinese market, said:"Oxford MESTAR will provide a flexible platform to respond quickly and efficiently to the opportunities for medical and healthcare technologies in the Chinese market. We are fortunate to be working with Simon Dai, a strategic and dynamic investor”.
Simon Dai, principal investor in the venture said: “By cooperating with Isis and Oxford, we are able to work closely with some of the best researchers in the field and access world-class facilities. Oxford MESTAR will be dedicated to developing and bringing to market promising biomedical technologies”.
Dr Rakesh Roshan, Technology Transfer Team Leader at Isis Innovation said: “We are delighted with the fact that Isis spin-outs continue to attract significant investment into the UK. Oxford MESTAR Limited has a novel commercialisation model, which will support technologies that may otherwise lack the necessary resources to reach the market”.
Tom Hockaday, Managing Director of Isis Innovation said: “We aim to work flexibly with academics and investors to structure promising businesses, of which Oxford MESTAR is a good example”.
Oxford MEStar is the ninth spin-out company from the Institute of Biomedical Engineering (IBME). The IBME, as part of the Department of Engineering Science, was established in 2008 and is located in the Old Road Campus in Headington, Oxford, the University's medical campus.